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ABSTRACT
In cutaneous T cell lymphomas (CTCL), miR-21 is aberrantly expressed in skin 
and peripheral blood and displays anti-apoptotic properties in malignant T cells. It is, 
however, unclear exactly which cells express miR-21 and what mechanisms regulate 
miR-21. Here, we demonstrate miR-21 expression in situ in both malignant and 
reactive lymphocytes as well as stromal cells. qRT-PCR analysis of 47 patients with 
mycosis fungoides (MF) and Sezary Syndrome (SS) confirmed an increased miR- 21 
expression that correlated with progressive disease. In cultured malignant T cells 
miR-21 expression was inhibited by Tofacitinib (CP-690550), a clinical-grade JAK3 
inhibitor. Chromatin immunoprecipitation (ChIP) analysis showed direct binding of 
STAT5 to the miR-21 promoter. Cytokine starvation ex vivo triggered a decrease 
in miR-21 expression, whereas IL-2 induced an increased miR-21 expression in 
primary SS T cells and cultured cytokine-dependent SS cells (SeAx). siRNA-mediated 
depletion of STAT5 inhibited constitutive- and IL-2- induced miR-21 expression in 
cytokine- independent and dependent T cell lines, respectively. IL-15 and IL-2 were 
more potent than IL-21 in inducing miR-21 expression in the cytokine-dependent 
T cells. In conclusion, we provide first evidence that miR-21 is expressed in situ in 
CTCL skin lesions, induced by IL-2 and IL-15 cytokines, and is regulated by STAT5 
in malignant T cells. Thus, our data provide novel evidence for a pathological role of 
IL-2Rg cytokines in promoting expression of the oncogenic miR-21 in CTCL.
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INTRODUCTION
Primary cutaneous T cell lymphomas (CTCL) 
represent a heterogeneous group of lymphoproliferative 
disorders characterized by proliferation of skin-homing 
malignant T cells in a chronic inflammatory environment 
[1]. The most prevalent clinical forms of CTCL are 
mycosis fungoides (MF) and the more aggressive leukemic 
variant, Sézary syndrome (SS) [1, 2]. The majority of the 
patients with MF presents with early stage disease (stage 
I-IIA), with approximately one third of them progressing 
to more advanced stages [3]. 
The etiology of CTCL is only partly understood, 
but the IL-2 receptor common gamma chain (IL-2Rgc), 
and its down-stream associated Janus kinases (JAKs) 
and Signal Transducers and Activators of Transcription 
(STATs) signaling pathways are frequently dysregulated 
and seem to play an important role in the pathogenesis 
and disease progression of CTCL [4]. Accordingly, the 
IL-2R is therapeutically targeted in CTCL by denileukin 
diftitox, an engineered combination of IL-2 and Diphtheria 
toxin (Ontac) [5]. High-affinity IL-2R´s are constitutively 
expressed on malignant T cells. In the early stages of 
CTCL the IL-2Rgc-signaling cytokines IL-2, IL-4, IL- 7, 
IL-15, and IL-21 activate STAT3 and/or STAT5, thus 
promoting malignant cell proliferation and survival [6–9] 
(and reviewed in ref. 4). While IL-2 and IL-15 appear 
to promote malignant cell proliferation in vivo, IL-21 
was reported to have both pro- and anti-tumor effects 
[4, 10, 11]. In advanced progressive CTCL, JAK3 and 
STAT3/STAT5 are constitutively activated in a cytokine 
independent manner [10, 12] (and reviewed in ref. 4) 
and believed to drive a multitude of pathological events 
involved in skin inflammation and disease progression. In 
addition to the well-established role in proliferation and 
anti-apoptosis, the JAK3/STAT pathway drives expression 
of regulatory and pro-inflammatory cytokines such as 
IL-5, IL-9, IL-10, IL-13, IL-17, IL-22, and lymphotoxin 
alpha, chemokines, and factors promoting angiogenesis 
[13–21]. Importantly, microbes have been implicated in 
disease progression in CTCL [22–24], and staphylococcal 
enterotoxins were recently shown to trigger aberrant 
JAK3/STAT3 signaling in malignant T cells [25] 
suggesting a direct link between bacterial infection/
colonization and activation of this oncogenic pathway in 
malignant T cells.
MicroRNAs (miRNA), non-coding single stranded 
RNAs of 20–25 nucleotides, constitute a novel class of 
gene regulators [26]. Altered regulation of miRNAs 
have important pathogenic implications in multiple 
malignancies [26]. Overexpressed miRNAs have been 
linked to cancer as tumor-promoting oncomiRs, while 
tumor-suppressive miRNAs are commonly downregulated 
in many cancers [26]. In CTCL miRNAs have primarily 
gained attention as diagnostic and prognostic markers 
and as regulators of malignant cell proliferation [27–32]. 
Recently, a three-miRNA diagnostic classifier was shown 
to distinguish between malignant and benign dermatoses 
with high accuracy [30]. Importantly, miR-155 was 
documented to be up-regulated in CTCL skin lesions and 
was associated with poor disease outcomes [32–34]. The 
activated form of STAT5 drives miR-155 expression, 
which in turn promotes proliferation of malignant T cells 
[27] indicating that miR-155 plays an oncomiR function 
in CTCL. In contrast, miR-22 is recognized as a tumor 
suppressor and is down-regulated in CTCL [35, 36] as 
well as in several other cancer types [37, 38]. 
miR-21 is one of the first discovered and most 
extensively studied miRNAs [39]. It is up-regulated in 
several hematological and solid-organ malignancies, 
displays anti-apoptotic properties [39] and promotes 
proliferation of CD4+ T cells [40, 41]. The hostgene of 
miR-21 (miR-21HG) is located within a coding gene 
(TMEM49) of the 17q23.2 chromosome region. Despite 
its intronic localization, it has its own promoter region 
and generates the primary transcript, pri-miR-21, which is 
independently regulated [42]. In contrast to several other 
oncomiRs, there is a good correlation between pri-miR-21 
and the mature miR-21 levels, suggesting that the key 
regulatory step for miR-21 expression and function occurs 
at the level of transcription [43].  miR-21 down-regulates 
tumor suppressor genes [44, 45], including PTEN in SS 
[46], and may serve as a diagnostic marker for human 
malignancy [47]. Interestingly, miR-21 also regulates the 
switch from inflammation to cancer [48], an important role 
that is also ascribed to miR-155 [49].  Recently, miR-21 
was found to be up-regulated via STAT3, involved in anti-
apoptosis in malignant T cells from SS patients [12] and 
associated with a poor prognosis [29].  Yet, the regulation 
and expression of miR-21 in CTCL remains poorly 
understood. Here, we provide the first evidence of in situ 
miR-21 expression in CTCL skin lesions, and demonstrate 
that miR-21 is up-regulated in lesional skin from CTCL 
patients and is associated with disease progression. In 
mechanistic experiments, we provide the evidence that 
miR-21 expression is induced by the IL-2Rg-binding 
cytokines IL-2 and IL-15, and is up-regulated directly by 
STAT5 in malignant T cells. Thus, these data suggest that 
miR-21 and its IL-2/IL-15/STAT5 regulators play a key 
role in the pathogenesis of CTCL and that miR-21 may 
serve as a potential therapeutic target in CTCL.     
RESULTS
Localization of miR-21 in CTCL skin lesions
The miR-21 expression is increased in skin lesions 
and peripheral blood in patients with CTCL [12, 32]; 
however it is unclear which cell populations express 
miR- 21. In situ hybridization analyses with a miR-21-
specific probe showed a strong cytoplasmatic staining 
of the lymphoid infiltrate in MF skin lesions in parallel 
Oncotarget3www.impactjournals.com/oncotarget
with weak background stain with the scrambled probe 
(examples in Figure 1). The miR-21 positive cells 
were localized in the epidermis, including Pautrier´s 
microabcesses, and the dermis. Notably, both large 
atypical T cells with neoplastic morphology and smaller 
lymphoid cells resembling reactive non-malignant 
T cells were labeled (Figure 1H). This suggests that both 
malignant and non-malignant T cells express miR-21 
in CTCL. Importantly, also the stromal cells including 
macrophages and epidermal keratinocytes stained positive 
supporting the notion that miR-21 is expressed by both 
malignant and non-malignant cells in the CTCL lesional 
tissue environment, as also seen in other cancers [50]. 
miR-21 is aberrantly expressed in CTCL skin 
lesions
Next, we investigated the expression of miR-21 in 
lesional- and non-lesional skin from 47 CTCL patients, 
and 21 healthy controls. As shown in Table 1, miR-21 
expression was 9-fold up-regulated in MF skin lesions as 
compared to healthy controls. The expression was also 
significantly increased (p = 0.027) in progressive disease 
as compared to patients who did not progress. These 
findings indicate that miR-21 is associated with disease 
progression, as suggested recently [31]. 
In SS patients, miR-21 is reportedly increased in 
the neoplastic CD4+ T cells circulating in peripheral blood 
[12]. However, miR-21 expression in skin lesions in these 
patients has not been previously quantified. As shown 
in Table 1, miR-21 was 6.3 fold increased in SS skin as 
compared to healthy controls, and significantly increased 
in lesional SS skin as compared with less affected SS 
skin in the same patients. These observations suggest that 
miR-21 could play a pathogenic role also in the cutaneous 
compartment of SS.  
Pri-miR-21 is constitutively expressed in 
malignant T cells and induced via the JAK3/
STAT3/STAT5 signaling pathway 
The JAK/STAT axis has been involved in the 
regulation of multiple miRNAs, including miR-21 in 
cancer [12, 48, 51]. To elucidate which signaling pathways 
drive miR-21 expression in CTCL, we examined the 
primary transcript of the miR-21 gene (miR-21HG/
C17q23.2; 55273409–55273480), pri-miR-21, in cultured 
malignant T cells (MyLa2059). As shown in Figure 2A, 
pri-miR-21 was constitutively expressed in MyLa2059. 
After inhibition of JAK3 by Tofacitinib (CP-690550), 
pri-miR-21 expression was down-regulated, suggesting 
that the JAK3/STAT pathway was involved in miR-21 
regulation. As expected [27], miR-155 expression was 
also down-regulated following JAK3 inhibition. Since 
JAK3 drives STAT3 and STAT5 activation in malignant 
T cells and both STAT proteins have been implicated in 
pri-miR-21 transcription in solid-organ cancers, we used 
siRNA-mediated depletion to address which of these STAT 
proteins regulated pri-miR-21 expression in malignant T 
cells. As shown in Figure 2B, siRNA mediated depletion 
of STAT3, decreased the expression of pri-miR-21. 
Likewise, depletion of STAT5 induced a similar decrease 
in pri-miR-21 expression, indicating that both STAT3 and 
STAT5 may be involved in the miR-21 up-regulation. 
To address whether STAT3 and STAT5 directly 
bind to the miR-21HG promoter in malignant T cells, 
we performed ChIP-seq to identify transcriptional targets 
of STAT3 and STAT5. ChIP-seq analysis of STAT5-
precipitated chromatin from malignant MyLa2059 
cells yielded a strong enrichment of reads comprising 
a region of the miR-21HG promoter (Figure 2C, upper 
part, second row), confirming recent findings that STAT5 
directly binds the miR-21HG and drives pri-miR-21 
expression in mammary alveolar epithelium [52]. In 
addition, our analysis of published STAT5 ChIP-seq 
and ChIP-chip datasets supports STAT5 regulation of 
the miR- 21 locus in human conventional and regulatory 
T cells (PMID: 24671953), CD8+ T cells (PMID: 
25992859) and erythroleukemic cells (PMID: 24681953) 
(Supplementary Figure S1). As expected [53], reads for 
the miR-21HG promoter were also detected in chromatin 
precipitated with STAT3 antibody (Figure 2C, upper 
part, first row) but the number was lower than in STAT5-
precipitated chromatin (Figure 2C, upper part, first row). 
The NFkB pathway is activated in malignant T cells 
(reviewed in [54] and as RelA and RelB drive pri-miR-21 
expression in some cancers like prostate cancer [53], 
we addressed whether this pathway was also involved. 
However, only a few reads were detected in chromatin 
precipitated with RelA and RelB (Figure 2C, middle part), 
and comparable to what was seen with a control antibody 
(Figure 2C, lower part). 
IL-2 induces miR-21 in malignant T cells
Since IL-2 activates STAT3 and STAT5 signaling 
via the IL-2Rg/JAK3 pathway [55], we studied whether 
IL-2 induced miR-21 expression in cytokine dependent 
T cells. We cultured malignant SS cells (SeAx) with IL-2 
for different time periods, and found a time-dependent 
increase in pri-miR-21 expression (Figure 3A) and a 
similar, yet delayed, up-regulation of the mature form 
of miR-21 (Figure 3B). Importantly, IL-2 also induced 
the expression of pri-miR-21 in primary malignant 
T cells (Figure 3C) isolated from peripheral blood and 
characterized (86% CD4+ CD26-) elsewhere [25]. 
As expected, IL-2 signaling resulted in an enhanced 
expression of pri-miR-155 [27], serving here as positive 
control (Figure 3C). In contrast, IL-2 had little effect 
on other miRs (such as pri-miR-326, pri-mir-34a and 
pri-miR-214) previously implicated in CTCL [29, 30] 
(Figure 3C, right columns). 
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Cytokine starvation induces a drop in miR-21 
expression
To address weather IL-2 starvation of cultured SeAx 
cells inhibited pri-miR-21 expression, cells were cultured 
in the presence or absence of IL-2 for 24 hours and 
assayed for pri-miR-21 expression. Indeed, pri-miR-21 
expression was decreased by 30% in response to IL-2 
starvation (Figure 4A). Although SeAx cells depend on 
IL-2 for continued growth, short term starvation (16–24 h) 
only resulted in a slight increase in apoptosis and decrease 
in protein content [17]. Importantly, a similar decrease 
in pri-miR-21 expression was observed when primary 
SS cells were cultured without IL-2 (Figure 4B). As 
expected, pri-miR-155 expression was also decreased after 
IL-2 deprivation (Figure 4B). Notably, the levels of pri-
miR-326 and pri-miR-34a expression were not influenced 
by IL-2 starvation (Figure 4B), suggesting that the 
Figure 1: In situ hybridization for miR-21 in mycosis fungoides. Intense miR-21 ISH signal is seen in the dermal infiltrate, and 
weaker miR-21 staining over epidermis, including the Pautrier´s microabcesses,  (A, C, E), whereas only background staining appeared for 
the scrambled control (B, D, F, H). Neoplastic lymphocytes (large atypical cells, example indicated by large arrow in G) and stromal cells, 
likely including macrophages, showed a cytoplasmatic staining for miR-21 (G). Similar findings were observed in other patient samples 
where neoplastic T-cells and stromal cells were stained for miR-21 (N = 10). 
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decrease in pri-miR-21 (and pri-miR-155) was specific and 
not a result of starvation induced apoptosis. Importantly, 
the decrease in pri-miR-21 and pri-miR-155 but not in 
pri-miR-326 and pri-miR-34a following IL-2 starvation 
mirrored the inverse pattern of pri-miR expression 
following IL-2 stimulation (Figure 3C) supporting the 
notion above that IL-2 drives miR-21 expression in a 
cytokine dependent manner in malignant T cells.     
JAK3, STAT3 and STAT5 promote miR-21 
expression in cytokine dependent malignant T cells
In order to extend the results described above, 
we examined miR-21 expression levels after siRNA-
mediated depletion of JAK3, STAT3 and STAT5 in 
cytokine-dependent malignant T cells (SeAx) cultured 
with IL-2. Inhibition of JAK3 decreased the pri-miR-21 
expression by 25% (Figure 5A). Similarly, inhibition of 
STAT3, STAT5A, and STAT5B resulted in reduction of 
the pri-miR-21 expression, although to a lesser degree for 
STAT5B, indicating that IL-2 induced miR-21 expression 
was, at least partly, mediated via a JAK3/STAT3/STAT5 
dependent pathway (Figure 5B). 
To elucidate the role of other IL-2Rg cytokines 
(IL-15 and IL-21) on miR-21 expression, we cultured 
malignant T cells (SeAx) with these cytokines for 24 
hours prior to analysis of miR-21 and miR-155 expression. 
As shown in Figure 5C, IL-2 and IL-15 induced a clear 
increase in miR-21 expression, whereas IL-21 induced 
only a minor increase in the expression after 24 hours, 
providing additional evidence suggesting that STAT5, 
rather than STAT3, plays a key role in cytokine-mediated 
miR-21 induction. Similarly, IL-2 and IL-15 induced 
miR-155 expression, whereas IL-21 did not, confirming 
the previous findings that these cytokines induce STAT5-
dependent miR-155 up-regulation [27]. Although IL- 21 
only induced a small increase in miR-21 expression 
after 24 hours, a substantial increase was observed after 
72 hours (data not shown) confirming previous findings 
by Vermeer and co-workers [12, 56].
DISCUSSION
miR-21 is well-described in cancer and believed 
to directly promote carcinogenesis through inhibition of 
tumor suppressors and enhancement of pro-oncogenic 
pathways, and indirectly, through induction of a tumor-
promoting inflammatory environment (reviewed in 
ref. 49). Recent studies demonstrated that miR-21 is also 
implicated in the pathogenesis of CTCL. Specifically, 
miR- 21 expression is enhanced in MF skin lesions 
[31, 32], and in primary SS cells [12, 29] and promotes 
survival of the malignant T cells. Yet, it remains poorly 
understood what drives its expression and exactly which 
cells express miR-21 within the lesional skin of CTCL. 
Here, we provide the first evidence that IL-2 induces 
miR- 21 expression in primary malignant T cells and 
T cell lines. Thus, we show that IL-2 induced a rapid 
up- regulation of pri-miR-21 and a delayed up-regulation 
of the mature miR-21. Conversely, IL-2 deprivation 
triggered a rapid decrease in pri-miR-21 expression, 
further supporting the critical role of IL-2 in the induction 
of miR- 21 expression in malignant T cells. Accordingly, 
a clinical-grade JAK3 inhibitor, Tofacitinib, strongly 
inhibited IL-2-induced miR-21 expression. 
We also investigated downstream transcription 
factors involved in miR-21 expression. Our results 
documented that inhibition of STAT3, STAT5A, and 
STAT5B by siRNA-mediated gene knockdown inhibited 
pri-miR-21 expression, suggesting that both IL-2 induced- 
and spontaneous- pri-miR-21 expression was mediated 
through the JAK3/STAT3/STAT5 signaling pathways. 
Notably, other members of the family of IL-2Rg-binding 
cytokines previously implicated in CTCL pathogenesis, 
IL-15 and IL-21, also induced pri-miR21 expression. 
However, whereas IL-15 induced a profound up-regulation 
Table 1: miR-21-5p expression in skin from mycosis fungoides- and Sézary Syndrome patients and 
healthy individuals
MF (N = 42) Fold change P
Progression vs non-progression 1.5 0.028
L vs N 9.0 < 0.0001
L vs NL 5.6 < 0.0001
SS (N = 5)
L vs N 6.3 0.003
L vs NL 1.5 0.005
MF, Mycosis fungoides; SS, Sézary syndrome; L, Lesional skin; 
NL, Non-lesional skin; N, Normal skin
FOOTNOTE: Progression was defined by presence of advanced CTCL (stage IIB-IVB) at diagnosis or later, and non-
progression as sustained early MF (Stage I-IIA) within the entire follow-up period (at least 5 years from onset of symptoms). 
Median follow-up time for the entire MF cohort was 7.8 years (range: 1.3; 32 years).
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Figure 2: Constitutive pri-miR-21 expression is regulated via JAK3/STAT3/STAT5 in the malignant T cell line 
MyLa2059. (A) Expression of pri-miR-21 and pri-miR-155 in MyLa2059 after treatment with JAK3 inhibitor (50 µmol/L) Tofacitinib, 
or DMSO control for 24 hours, measured by qRT-PCR. N = 3. (B) pri-miR-21 expression after siRNA mediated knock-down of STAT3 and 
STAT5A and STAT5B in MyLa2059 cells as measured by qRT-PCR. (N = 3). (C) ChIP-seq reads from the miR21HG promoter region in 
malignant MyLa2059 cells. Reads obtained from immunoprecipitation with STAT5, STAT3, RelB, RelA and a negative control (Rabbit IgG 
antibody, bottom). Forward reads are indicated in green and reverse reads in red. 
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of pri-miR-21 expression comparable to that seen in 
IL- 2-treated cells, IL-21 induced only a weak pri-miR-21 
response. 
Since IL-15 activates both STAT3 and STAT5 
signaling, while IL-21 only activates STAT3, these 
findings suggest that STAT5 plays a key role in pri-miR-21 
expression. Although IL-21 only induced a small increase 
in miR-21 expression after 24 hours, a substantial increase 
was observed after 72 hours (data not shown) suggesting 
that IL-21/STAT3 mediated miR-21 expression might 
involve an indirect mode of action. Our ChIP-seq analysis 
indicates that STAT5-immunoprecipitation significantly 
enriched chromatin associated with the miR-21HG 
promoter, whereas control antibodies did not, thus support 
a direct role for STAT5 in pri-miR-21 transcription. 
Consistent with this, other studies have demonstrated 
STAT5 occupancy of the miR-21 locus in distinct 
cellular contexts (PMID: 24671953, 25992859, PMID: 
24681953). Our findings of only a modest enrichment of 
chromatin associated the miR-21HG promoter in STAT3-
immonuprecipitats suggest that STAT3 may also regulate 
miR-21 expression through an indirect way. Interestingly, 
STAT3 was previously found to enhance miR-21 
expression in some studies and repress miR-21 expression 
in others [12, 35, 51, 57, 58] suggesting a complex and 
cell context specific role of STAT3 in regard to the miR-21 
expression. An extra layer of complexity arises from the 
observation that STAT3 is a miR-21 target itself. Thus, it 
is likely that STAT3 and miR-21 engage in a dynamic and 
complex feed-back/feed-forward regulation – a possibility, 
which may explain in part the discrepancies regarding the 
exact role of STAT3 in miR-21 expression. 
Taken together, our results suggest that IL-2 and 
IL- 15 induce pri-miR-21 expression via the JAK3/STAT5/
STAT3 pathway. Thus, they provide the first mechanistic 
link between these two well-established CTCL growth 
factors and miR-21, a recently identified key player in anti-
apoptosis in malignant T cells. Since advanced disease is 
invariably associated with increased JAK/STAT3/STAT5 
activation in situ, our findings may also provide a direct 
Figure 3: Effect of IL-2 on primary- and mature miR-21 expression in cytokine dependent T cells (SeAx) and primary 
Sézary T cells. Expression of pri-miR-21 (A) and mature miR-21 (B) in SeAx cells cultured in the presence or absence of IL-2 for up 
to 72 hours, measured by qRT-PCR. N = 3. (C) Primary Sézary cells cultured with IL-2 for 16 hours followed by qRT-PCR analysis of the 
expression of pri-miR-21, pri-miR-155, pri-miR-326, pri-miR-34a, pri-miR-214, and pri-miR-142. 
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explanation for the association between increased levels 
of miR-21 expression and disease progression. Of notice, 
our observation that the effect of IL-2 stimulation and 
IL-2 starvation was bigger than the effect of JAK/STAT 
blockage indicated that additional factors are involved in 
IL-2-mediated miR-21 expression. As Muppala et al [59] 
recently reported on Src mediated miR-21 expression 
in colorectal cancer cells and it is well-known that IL-2 
activates Src kinases such as Lck, we speculate that Src 
kinases migh also be involved in IL-2 and IL-15- mediated 
miR-21 expression.  
Although it is well established that miR-21 
expression is enhanced in CTCL lesions, it remained 
unknown, which cell types in the skin lesion express 
miR-21. Now, we show that miR-21 is expressed in situ 
by malignant T cells, smaller lymphoid cells resembling 
reactive non-malignant T cells, and by stromal cells in 
CTCL skin lesions. These findings show that not only 
the malignant T cells, but also non-malignant T cells 
and stromal cells are aberrantly activated and contribute 
to the global miR-21 expression in lesional skin. Since 
miR-21 promotes inflammation and inhibits apoptosis, 
Figure 4: Effect of IL-2 starvation on primary- and mature miR-21 expression in cytokine-dependent T cells (SeAx) 
and primary Sézary T cells. (A) pri-miR-21 expression in SeAx cells cultured with IL-2 as control and without IL-2 for 24 hours, 
N = 3. (B) Primary Sézary cells cultivated overnight in the presence or absence of IL-2 followed by assessment of the pri-miR-21, pri-
miR-155, pri-miR-326 and pri-miR-34a expression by qRT-PCR.
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it is likely that the simultaneous miR-21 expression in 
multiple cell types is more efficient in fostering a tumor-
promoting environment in the affected skin tissue. A 
coordinated up-regulation of miR-21 in both cancer- and 
stromal- cells is not unique to CTCL lesions. On the 
contrary, similar findings have been reported previously 
in solid tumors such as colorectal cancer [50]. Of notice, 
miR-21 has been implicated in many aspects of cancer 
pathobiology. For instance, miR-21 promotes genetic 
instability, sustained proliferation, and apoptosis evasion 
in cancer cells, enhances angiogenesis, and deregulates 
cytokine expression by macrophages and stromal cells 
[60]. Therefore, it is likely that a coordinated up-
regulation of miR-21 by malignant and stromal cells 
act in synergy to promote a tumor permissive micro-
environment in CTCL [39]. 
miR-21 is expressed in situ in epidermal 
keratinocytes and promotes keratinocyte proliferation in 
mice [61]. miR-21 is an important downstream component 
of BMP signalling in epidermal keratinocytes [61]. 
Moreover, miR-21 is up-regulated in hyperproliferative 
epidermal disorders [62] and expressed in situ in human 
epidermal keratinocytes in chronic wounds inhibiting 
epithelialization and wound healing in an ex vivo acute 
human skin wound model and in vivo in a rat wound 
model [63]. Induction of specific miRs inhibits cutaneous 
Figure 5: JAK3/STAT3 and STAT5 regulate miR-21 expression in cytokine dependent T cells. (A) pri-miR-21 expression 
in SeAx cells cultured with IL-2 and treated with JAK3 inhibitor Tofacitinib (50 µmol/L). N = 5, p < 0.05 (Wilcoxon signed rank test). 
(B) pri-miR-21 expression after siRNA mediated knock-down of STAT3, STAT5A and STAT5B in SeAx cells cultured with IL-2. N = 5, 
p < 0.05 (Wilcoxon signed rank test).  (C) Expression of miR-21 and miR-155 in SeAx cells cultured with the IL-2Rg cytokines IL-2, IL-15 
and IL-21 for 24 hours. Data are shown from one experiment.
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wound healing [63]. Accordingly, we propose that miR- 21 
expression in epidermal keratinocytes may also play a 
role in epidermal hyperproliferation and ulcer formation 
in CTCL.
In this context, our finding showing that enhanced 
miR-21 expression is associated with progressive disease 
is likely to reflect an increased expression of miR-21 in 
malignant T cells, as well as in non-malignant T cells 
and stromal cells. Indeed, malignant T cells often express 
IL- 15 and IL-21 and may thus induce miR-21 expression 
by infiltrating, non-malignant T cells [4–8, 12]. Likewise, 
keratinocytes express IL-15 in situ in CTCL lesions 
[6] suggesting the possibility of a miR- 21 promoting 
paracrine crosstalk between keratinocytes, malignant- and 
non-malignant T cells. Accordingly, we hypothesize that 
miR-21 has the potential of becoming an important future 
therapeutic target for treatment in CTCL, since miR-21 
blockade is expected to inhibit not only the malignant 
T cells, but also the tumor-promoting environment. Several 
lines of evidence indicate that miR-21 is also a disease 
driver in other lymphomas and solid cancers. Indeed, high 
miR-21 expression – in situ, is an independent prognostic 
factor in DLBCL and NHL as well as solid cancers such as 
glioma-, pancreatic-, renal- and colorectal cancer [64–71]. 
In conclusion, we provide the first evidence that 
miR-21 expression in malignant CTCL cells is (i) induced 
by IL-2 and IL-15, key growth factors for malignant 
T cells, (ii) mediated via STAT5, and (iii) inhibited by 
a clinical grade JAK3 inhibitor. Furthermore, we show 
that miR-21 is expressed in situ by both malignant T 
cells and stromal cell and even in non-lesional skin from 
MF patients. Taken together, these findings support the 
notions that miR-21 plays a key role in the pathogenesis 
and progression of CTCL and may serve as a potential 
therapeutic target in CTCL.
MATERIALS AND METHODS
Patients and tissue samples 
A cohort of 47 CTCL patients, 42 MF patients 
and 5 SS patients, and 21 healthy sex- and age-matched 
controls, were identified and included after informed 
consent was obtained. Four-millimeter punch biopsies 
were collected, as paired samples from the same body 
region, from lesional- and non-lesional MF skin, and from 
healthy controls. For patients with SS the biopsies were 
collected from lesional skin and from less affected skin 
from the same body region. The samples were immediately 
snap frozen in liquid nitrogen. The MF disease history was 
reviewed in medical records and patients were divided 
into two cohorts; a cohort of 21 MF patients displaying 
progressive disease and a cohort of 21 MF patients with 
non-progressive disease. Progression was defined by 
presence of advanced CTCL (stage IIB-IVB) at diagnosis 
or later, and non-progression as sustained early MF 
(Stage I-IIA) within the entire follow-up period (at least 
5 years from onset of symptoms). Median follow-up 
time for the entire MF cohort was 7.8 years (range: 1.3; 
32 years). The MF diagnosis was histologically verified 
for all patients, and they were staged according to the 
WHO-EORTC/ISCL staging system [72]. The study was 
conducted in accordance with the Declaration of Helsinki 
and approved by the Regional Ethical Committee of 
Region Midtjylland (M-20090102). 
In situ hybridization 
Six μm thick tissue sections from paraffin 
embedded lesional MF skin biopsies were used for 
in situ hybridization as described elsewhere [50, 73]. 
In brief, the slides were deparaffinized and placed in a 
Tecan Freedom Evo automated hybridization instrument 
(Tecan, Männedorf, Switzerland), which was programmed 
to perform the following steps: proteinase-K treatment 
using 15 μg/mL for 8 min at 37oC, pre-hybridization in 
formamide-free hybridization buffer (Exiqon, Vedbæk, 
Denmark) at 57°C for 15 min, in situ hybridization with 
double-FAM-labeled miR-21 and scramble LNA probes 
(both at 40nM, Exiqon) at 57oC for 60 min, stringent 
washes with SSC buffers at 57°C over 33 min followed 
by incubation of alkaline phosphatase-conjugated anti-
FAM, NBT-BCIP substrate (all from Roche, Mannheim, 
Germany), and finally nuclear fast red counterstain (Vector 
Laboratories, Burlingname, CA, USA). Finally, all slides 
were dehydrated and the sections mounted with Eukitt 
(Electron Microscopy Sciences, Hatfield, PA, USA). 
Cell lines and culture
The malignant T cell lines, MyLa2059 and SeAx, 
were derived from MF skin lesions and PBMC´s from 
SS patients, respectively, and have been previously 
characterized [74]. Both cell lines were cultured in 
RPMI1640 medium (Sigma-Aldrich) supplemented with 
5% penicillin/streptomycin (Sigma-Aldrich). In addition, 
the medium was supplemented with 10% Fetal Bovine 
Serum for MyLa2059 cells and 10% Human Serum for 
SeAx cells. The SeAx cells were cultured in the presence 
or absence of IL-2 (103U/mL IL-2, Novartis). Peripheral 
blood mononuclear cells (PBMCs) were isolated from 
a patient diagnosed with SS using a Ficoll Gradient, 
Lymphoprep (Axis-Shield PoC AS), as previously 
described [17] and cultured as described for SeAx cells. 
JAK3 inhibitor, Tofacitinib (CP-690550, Pfizer), was used 
in experiments with MyLa2059 and SeAx cells. 
Chromatin Immunoprecipitation (ChIP) 
sequencing (ChIPseq)
Chromatin Immune-Precipitation followed by DNA 
sequencing (ChIPseq) was performed using SimpleChIP® 
Oncotarget11www.impactjournals.com/oncotarget
Enzymatic Chromatin IP kit (Agarose Beads) from Cell 
Signaling Technologies as previously described [27]. 
Cross-linked chromatin fragments were captured with 
antibodies against STAT3, STAT5, RelB, RelA, Histone 
H3 (positive control) or Rabbit IgG (negative control). 
Library construction and sequencing has been described 
in detail in Kopp et al. [27]. 
Transient transfections with siRNA
2 × 106 cells per sample were transfected with 
small interfering RNA (siRNA) against STAT3, STAT5A, 
STAT5B or non-targeting control (ON-TARGETplus 
SMARTpool, Thermo Scientific). Cell pellets were 
resuspended in 100 μL transfection solution (Ingenio 
Electroporation solution, Mirus) with 0.5 nmol of the 
respective siRNAs and transfected with an Amaxa 
Nucleofector (AMAXa Gmbh, Germany).
Cell RNA extraction and qRT-PCR
Total RNA was purified from cells using miRNeasy 
Mini Kit (Qiagen). RNA (10ng) was transcribed into 
cDNA using TaqMan® miRNA Reverse Transcription Kit 
(Applied Biosystems), and qRT-PCR was performed using 
TaqMan® miRNA assays (Applied Biosystems) for mature 
miR´s, according to the manufacturer’s instructions and as 
described elsewhere [75]. U6 was used as reference gene. 
For quantification of pri-miR-21 expression, RNA was 
transcribed to cDNA using High Capacity cDNA Reverse 
Transcription Kit, followed by qRT-PCR performed using 
TaqMan® Gene Expression Assays (Applied Biosystems), 
according to the manufacturer’s instructions. GAPDH 
(Applied Biosystems) was included as a reference gene. 
The PCR amplification was performed on a Mx3005P 
qPCR System (Agilent Technologies) real-time cycler, 
using standard settings. Each experiment included three 
technical replicates. Results are presented as a relative 
quantity in comparison to the control samples based on 
ddCt method calculations.
qRT-PCR panel assay
Total RNA was extracted from 4 mm skin biopsies 
from the cohort of 47 CTCL patients and 21 matched 
controls using miRNeasy Mini kit (Qiagen) according 
to the manufacturer´s instructions. RNA (40 ng) from 
each patient was reverse transcribed to cDNA in 40μl 
reactions using universal cDNA synthesis kit (Exiqon, 
Vedbaek, Denmark). cDNA was diluted 100x and assayed 
in 10 μl PCR reactions using SYBR green mastermix 
in microRNA Ready-to-Use PCR, panel I and panel II, 
version 3R (Exiqon, http://www.exiqon.com/mirna-pcr). 
cDNA and SYBR Green mastermix were transferred to 
the qPCR panels preloaded with primers, using a pipetting 
robot (Exiqon, Vedbaek, Denmark). Amplification was 
performed in a Roche LightCycler480 in 2x384 well 
plates. The Roche LightCycler software was used to 
calculate the crossing point (Cp) value and to perform 
melting curve analysis for each miR in every sample. miRs 
detected at fewer than 5 Cps compared to the negative 
control or with Cps above 37, were excluded from further 
analysis. The PCR amplification specificity was evaluated 
by melting curve analysis. Reactions with a single melting 
point in the expected range were accepted for further 
analysis and reactions not reaching these criteria were 
omitted. Finally, reactions with PCR amplification efficacy 
below 1.6 were excluded from further analysis, evaluated 
using algorithms similar to the LinReg software.
Statistics
The expression level of each miR in the qRT-PCR 
panels was normalized to the average of assays detected 
in all samples (n = 82) (average – assay Cp), which was 
identified as the best normalizer, using NormFinder 
software. Fold-change was calculated using the 2-ΔΔCp 
method. A Student´s t-test was used to assess the 
significance of difference between expression levels in the 
qRT-PCR panel. In mechanistic experiments on the effect 
of cytokines, inhibitors and siRNAs, the Wilcoxon signed 
rank test was used. p-value less than 0.05 were considered 
significant and indicated in figure legends, if not otherwise 
specified. 
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Supplementary Figure S1: The NCBI-GEO database (http://www.ncbi.nlm.nih.gov/geo/) was searched for STAT5 
chromatin-immunoprecipitation (ChIP) coupled with next generation sequencing (ChIPseq) or array (ChIP-chip).
Peaks (in BED) format were converted to HG18 coordinates using the UCSC-Liftover tool where necessary and visualized 
using the Integrated Genome Viewer. (http://www.ncbi.nlm.nih.gov/geo/). STAT5B occupancy of the miR21 locus (indicated in 
red) is and IL2 stimulated (GSM1577746) pre-activated CD8+ T cells; control (GSM671401) evident in human conventional T cells 
(GSM1056924, GSM1056925), human T regulatory cells (GSM056922, GSM1056923); control (GSM1577745) and IL2 stimulated 
(GSM671402) Th1 T cells and human erythroleukemic cells (GSM935806). Interestingly, STAT5B coincides with p53 at the miR21 locus 
in human leukemic cells (GSM935809).
